The invention relates to bacterial strains, particularly for use in the field of vaccines, in particular to the field of the prevention or treatment of infections caused by bacterium of the Bordetella genus.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens originating from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.

The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens originating from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.

Bordetella pertussis iron receptor proteins or portions thereof (e.g., one or more extracellular domains), alone or spliced into B. pertussis scaffold proteins (e.g., fimbrial or flagellin), are provided and can be used in acellular vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals. In addition, Bordetella species grown under iron-starved conditions are provided and can be used in whole cell vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals.

Bordetella pertussis iron receptor proteins or portions thereof (e.g., one or more extracellular domains), alone or spliced into B. pertussis scaffold proteins (e.g., fimbrial or flagellin), are provided and can be used in acellular vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals. In addition, Bordetella species grown under iron-starved conditions are provided and can be used in whole cell vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals.